Biocon
Saurabh Paliwal possesses extensive experience in investor relations, holding prominent positions at leading healthcare organizations. Currently, Saurabh serves as the Head of Investor Relations in the CEO’s Office at Biocon, focusing on strategic imperatives. Previously, Saurabh led investor relations at Aster DM Healthcare and worked as General Manager and Deputy General Manager at Biocon. Prior roles include Deputy General Manager of Investor Relations at GVK and Vice President of Investor Relations at A2Z Maintenance & Engineering Services Limited. Saurabh holds an MBA in Marketing from The Ohio State University Fisher College of Business and an M.Sc. in Biotechnology from Savitribai Phule Pune University.
This person is not in any teams
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.